Anti-malarial activity of geldanamycin derivatives in mice infected with Plasmodium yoelii

Malaria Journal

Volumn 11, Issue , 2012, Pages

  Mout, Rubul ^a   Xu, Zhi Dong ^c   Wolf, Angela K H ^b   Jo Davisson, Vincent ^b,c   Jarori, Gotam K ^a  

^a TATA INSTITUTE OF FUNDAMENTAL RESEARCH   (India)

^b PURDUE UNIVERSITY   (United States)

^c PURDUE UNIVERSITY   (United States)

Author keywords

Geldanamycin; Immunity; Normocyte; Plasmodium yoelii; Reticulocyte

Indexed keywords

17 N [3 [2 [2 (3 AMINOPROPOXY)ETHOXY]PROPYL]PENT 4 YNAMIDE] 17 DEMETHOXYGELDANAMYCIN; ANTIBIOTIC AGENT; ANTIMALARIAL AGENT; CHLOROQUINE; HEAT SHOCK PROTEIN 90 INHIBITOR; PROTEIN ANTIBODY; PROTOZOAL PROTEIN; RETASPIMYCIN; UNCLASSIFIED DRUG; BENZOQUINONE DERIVATIVE; GELDANAMYCIN; MACROCYCLIC LACTAM; PROTOZOON ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIMALARIAL ACTIVITY; ARTICLE; BIOLOGICAL MONITORING; BLOOD SAMPLING; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ERYTHROCYTE; EXPERIMENTAL MODEL; IMMUNE RESPONSE; INFECTION RESISTANCE; MOUSE; NONHUMAN; PARASITE VIRULENCE; PARASITEMIA; PLASMODIUM YOELII; PLASMODIUM YOELII INFECTION; PROTECTION; RETICULOCYTE; SCHIZONT; TROPHOZOITE; ANIMAL; BLOOD; DISEASE MODEL; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; MALARIA; PARASITE LOAD; PARASITOLOGY; TREATMENT OUTCOME; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIMALARIALS; BENZOQUINONES; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; LACTAMS, MACROCYCLIC; MALARIA; MICE; PARASITE LOAD; PLASMODIUM YOELII; TREATMENT OUTCOME;

EID: 84861565337     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-11-54     Document Type: Article

References (53)

1. WHO, http://www.who.int/malaria/world-malaria-report-2010/ worldmalariareport2010.pdf
2. Adult and child malaria mortality in India: a nationally representative mortality survey. Dhingra N, Jha P, Sharma VP, Cohen AA, Jotkar RM, Rodriguez PS, Bassani DG, Suraweera W, Laxminarayan R, Peto R, Lancet 2010 376 1768 1774 10.1016/S0140-6736(10)60831-8 20970179
3. Recent insights into humoral and cellular immune responses against malaria. Beeson JG, Osier FH, Engwerda CR, Trends Parasitol 2008 24 578 584 10.1016/j.pt.2008.08.008 18848497
4. Acquired immunity to malaria. Doolan DL, Dobano C, Baird JK, Clin Microbiol Rev 2009 22 13 36 10.1128/CMR.00025-08 19136431
5. Malaria vaccines: are we getting closer? Epstein JE, Giersing B, Mullen G, Moorthy V, Richie TL, Curr Opin Mol Ther 2007 9 12 24 17330398
6. Medical need, scientific opportunity and the drive for antimalarial drugs. Ridley RG, Nature 2002 415 686 693 10.1038/415686a 11832957
7. Antimalarial drug resistance: ramifications, explanations and challenges. Ridley RG, Microbes Infect 2002 4 155 156 10.1016/S1286-4579(01)01536-2 11880046
8. Mechanisms of resistance of Plasmodium falciparum to antimalarial drugs. Hyde JE, Microbes Infect 2002 4 165 174 10.1016/S1286-4579(01)01524-6 11880048
9. Drug-resistant malaria. Hyde JE, Trends Parasitol 2005 21 494 498 10.1016/j.pt.2005.08.020 16140578
10. Drug-resistant malaria-an insight. Hyde JE, Febs J 2007 274 4688 4698 10.1111/j.1742-4658.2007.05999.x 17824955
11. Genome sequence of the human malaria parasite Plasmodium falciparum. Gardner MJ, Hall N, Fung E, White O, Berriman M, Hyman RW, Carlton JM, Pain A, Nelson KE, Bowman S, Paulsen IT, James K, Eisen JA, Rutherford K, Salzberg SL, Craig A, Kyes S, Chan MS, Nene V, Shallom SJ, Suh B, Peterson J, Angiuoli S, Pertea M, Allen J, Selengut J, Haft D, Mather MW, Vaidya AB, Martin DM, Fairlamb AH, Fraunholz MJ, Roos DS, Ralph SA, McFadden GI, Cummings LM, Subramanian GM, Mungall C, Venter JC, Carucci DJ, Hoffman SL, Newbold C, Davis RW, Fraser CM, Barrell B, Nature 2002 419 498 511 10.1038/nature01097 12368864
12. Structure-based approaches to the development of novel anti-malarials. Brady RL, Cameron A, Curr Drug Targets 2004 5 137 149 10.2174/1389450043490587 15011947
13. Spiroindolones, a potent compound class for the treatment of malaria. Rottmann M, McNamara C, Yeung BK, Lee MC, Zou B, Russell B, Seitz P, Plouffe DM, Dharia NV, Tan J, Cohen SB, Spencer KR, González-Páez GE, Lakshminarayana SB, Goh A, Suwanarusk R, Jegla T, Schmitt EK, Beck HP, Brun R, Nosten F, Renia L, Dartois V, Keller TH, Fidock DA, Winzeler EA, Diagana TT, Science 2010 329 1175 1180 10.1126/science.1193225 20813948
14. Geldanamycin, a new antibiotic. DeBoer C, Meulman PA, Wnuk RJ, Peterson DH, J Antibiot (Tokyo) 1970 23 442 447 10.7164/antibiotics.23.442
15. Plasmodial heat shock proteins: targets for chemotherapy. Shonhai A, FEMS Immunol Med Microbiol 2010 58 61 74 10.1111/j.1574-695X.2009.00639.x 20041948
16. Effects of geldanamycin and its derivatives on RNA-directed DNA polymerase and infectivity of Rauscher leukemia virus. Li LH, Clark TD, Cowie CH, Rinehart KL Jr, Cancer Treat Rep 1977 61 815 824 70272
17. Inhibition of heat shock protein HSP90-pp 60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM, Proc Natl Acad Sci USA 1994 91 8324 8328 10.1073/pnas.91.18.8324 8078881
18. Chaperoning a cellular upheaval in malaria: heat shock proteins in Plasmodium falciparum. Acharya P, Kumar R, Tatu U, Mol Biochem Parasitol 2007 153 85 94 10.1016/j.molbiopara.2007.01.009 17307260
19. Heat shock protein 90 function is essential for Plasmodium falciparum growth in human erythrocytes. Banumathy G, Singh V, Pavithra SR, Tatu U, J Biol Chem 2003 278 18336 18345 10.1074/jbc.M211309200 12584193
20. The heat shock protein 90 of Plasmodium falciparum and antimalarial activity of its inhibitor, geldanamycin. Kumar R, Musiyenko A, Barik S, Malar J 2003 2 30 10.1186/1475-2875-2-30 14514358
21. Plasmodium falciparum calcineurin and its association with heat shock protein 90: mechanisms for the antimalarial activity of cyclosporin A and synergism with geldanamycin. Kumar R, Musiyenko A, Barik S, Mol Biochem Parasitol 2005 141 29 37 10.1016/j.molbiopara.2005.01.012 15811524
22. Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Supko JG, Hickman RL, Grever MR, Malspeis L, Cancer Chemother Pharmacol 1995 36 305 315 10.1007/BF00689048 7628050
23. Phase I and pharmacologic study of 17-(allylamino)-17- demethoxygeldanamycin in adult patients with solid tumors. Grem JL, Morrison G, Guo XD, Agnew E, Takimoto CH, Thomas R, Szabo E, Grochow L, Grollman F, Hamilton JM, Neckers L, Wilson RH, J Clin Oncol 2005 23 1885 1893 10.1200/JCO.2005.12. 085 15774780
24. Measurement of the novel antitumor agent 17-(allylamino)-17- demethoxygeldanamycin in human plasma by high-performance liquid chromatography. Agnew EB, Wilson RH, Grem JL, Neckers L, Bi D, Takimoto CH, J Chromatogr B Biomed Sci Appl 2001 755 237 243 10.1016/S0378-4347(01)00113-X 11393709
25. Synthesis and biological activities of novel 17-aminogeldanamycin derivatives. Tian ZQ, Liu Y, Zhang D, Wang Z, Dong SD, Carreras CW, Zhou Y, Rastelli G, Santi DV, Myles DC, Bioorg Med Chem 2004 12 5317 5329 10.1016/j.bmc.2004.07.053 15388159
26. Sub-cellular localization and post-translational modifications of the Plasmodium yoelii enolase suggest moonlighting functions. Pal-Bhowmick I, Vora HK, Jarori GK, Malar J 2007 6 45 10.1186/1475-2875-6-45 17437631
27. Cloning, over-expression, purification and characterization of Plasmodium falciparum enolase. Pal-Bhowmick I, Sadagopan K, Vora HK, Sehgal A, Sharma S, Jarori GK, Eur J Biochem 2004 271 4845 4854 10.1111/j.1432-1033.2004.04450.x 15606772
28. Enhanced expression of H-2 K and H-2D antigens on reticulocytes infected with Plasmodium yoelii. Jayawardena AN, Mogil R, Murphy DB, Burger D, Gershon RK, Nature 1983 302 623 626 10.1038/302623a0 6339952
29. Plasmodium yoelii uses the murine Duffy antigen receptor for chemokines as a receptor for normocyte invasion and an alternative receptor for reticulocyte invasion. Swardson-Olver CJ, Dawson TC, Burnett RC, Peiper SC, Maeda N, Avery AC, Blood 2002 99 2677 2684 10.1182/blood.V99.8.2677 11929753
30. Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. Basso AD, Solit DB, Chiosis G, Giri B, Tsichlis P, Rosen N, J Biol Chem 2002 277 39858 39866 10.1074/jbc.M206322200 12176997
31. Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Basso AD, Solit DB, Munster PN, Rosen N, Oncogene 2002 21 1159 1166 10.1038/sj.onc.1205184 11850835
32. Structure, function, and mechanism of the Hsp90 molecular chaperone. Pearl LH, Prodromou C, Adv Protein Chem 2001 59 157 186 11868271
33. Hsp90: chaperoning signal transduction. Richter K, Buchner J, J Cell Physiol 2001 188 281 290 10.1002/jcp.1131 11473354
34. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. Banerji U, O'Donnell A, Scurr M, Pacey S, Stapleton S, Asad Y, Simmons L, Maloney A, Raynaud F, Campbell M, Walton M, Lakhani S, Kaye S, Workman P, Judson I, J Clin Oncol 2005 23 4152 4161 10.1200/JCO.2005.00.612 15961763
35. Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors. Goetz MP, Erlichman C, Windebank AJ, Reid JM, Sloan JA, Atherton P, Adjei AA, Rubin J, Pitot H, Galanis E, Ames MM, Goldberg RM, J Clin Oncol 2003 21 3761 3769 10.1200/JCO.2003.01.238 12963697
36. A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer. Nowakowski GS, McCollum AK, Ames MM, Mandrekar SJ, Reid JM, Adjei AA, Toft DO, Safgren SL, Erlichman C, Clin Cancer Res 2006 12 6087 6093 10.1158/1078-0432.CCR-06-1015 17062684
37. The heat shock protein 90 of Leishmania donovani. Wiesgigl M, Clos J, Med Microbiol Immunol 2001 190 27 31 11770104
38. Heat shock protein 90 homeostasis controls stage differentiation in Leishmania donovani. Wiesgigl M, Clos J, Mol Biol Cell 2001 12 3307 3316 11694568
39. Hsp90 is essential in the filarial nematode Brugia pahangi. Devaney E, O'Neill K, Harnett W, Whitesell L, Kinnaird JH, Int J Parasitol 2005 35 627 636 10.1016/j.ijpara.2005.01.007 15862576
40. In vitr activity of geldanamycin derivatives against Schistosoma japonicum and Brugia malayi. Wenkert D, Ramirez B, Shen Y, Kron MA, J Parasitol Res 2010 2010 716498 21253549
41. Expression of a unique drug-resistant Hsp90 ortholog by the nematode Caenorhabditis elegans. David CL, Smith HE, Raynes DA, Pulcini EJ, Whitesell L, Cell Stress Chaperones 2003 8 93 104 10.1379/1466-1268(2003)8<93:EOAUDH>2. 0.CO;2 12820659
42. Hsp-90 and the biology of nematodes. Him NA, Gillan V, Emes RD, Maitland K, Devaney E, BMC Evol Biol 2009 9 254 10.1186/1471-2148-9-254 19849843
43. Immunization of man against sporozite-induced falciparum malaria. Clyde DF, Most H, McCarthy VC, Vanderberg JP, Am J Med Sci 1973 266 169 177 10.1097/00000441-197309000-00002 4583408
44. Genetically engineered, attenuated whole-cell vaccine approaches for malaria. Vaughan AM, Wang R, Kappe SH, Hum Vaccin 2010 6 107 113 10.4161/hv.6.1.9654 19838068
45. http://www.who.int/vaccine-research/links/Rainbow/en/index.html
46. Malaria vaccines and their potential role in the elimination of malaria. Targett GA, Greenwood BM, Malar J 2008 7 Suppl 1 10 10.1186/1475-2875-7-S1-S10 19091034
47. The mysteries of immunity to malaria. Greenwood B, Targett G, Lancet 2011 377 1729 1730 10.1016/S0140-6736(11)60515-1 21514657
48. Empowering malaria vaccination by drug administration. Sauerwein RW, Bijker EM, Richie TL, Curr Opin Immunol 2010 22 367 373 10.1016/j.coi.2010.04. 001 20434895
49. Protection against a malaria challenge by sporozoite inoculation. Roestenberg M, McCall M, Hopman J, Wiersma J, Luty AJ, van Gemert GJ, van de Vegte-Bolmer M, van Schaijk B, Teelen K, Arens T, et al. N Engl J Med 2009 361 468 477 10.1056/NEJMoa0805832 19641203
50. Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study. Roestenberg M, Teirlinck AC, McCall MB, Teelen K, Makamdop KN, Wiersma J, Arens T, Beckers P, van Gemert G, van de Vegte-Bolmer M, van der Ven AJ, Luty AJ, Hermsen CC, Sauerwein RW, Lancet 2011 377 1770 1776 10.1016/S0140-6736(11)60360-7 21514658
51. Erythrocyte binding ligands in malaria parasites: intracellular trafficking and parasite virulence. Culleton R, Kaneko O, Acta Trop 2010 114 131 137 10.1016/j.actatropica.2009.10.025 19913491
52. Single amino acid substitution in Plasmodium yoeliierythrocyte ligand determines its localization and controls parasite virulence. Otsuki H, Kaneko O, Thongkukiatkul A, Tachibana M, Iriko H, Takeo S, Tsuboi T, Torii M, Proc Natl Acad Sci USA 2009 106 7167 7172 10.1073/pnas.0811313106 19346470
53. Sudden increase in virulence in a strain of Plasmodium berghei yoelii. Yoeli M, Hargreaves B, Carter R, Walliker D, Ann Trop Med Parasitol 1975 69 173 178 1098585